Abstract
Thirty-eight patients with primary obsessive-compulsive disorder participated in a 10-week, double-blind, placebo-controlled trial of the potent, selective serotonin reuptake inhibitor fluvoxamine. Fluvoxamine was significantly better than placebo on two of three measures of improvement in obsessive-compulsive symptoms. The authors also compared studies of the serotonergic agents fluvoxamine, sertraline, fluoxetine, and clomipramine and found that a greater effect size was associated with less serotonergic specificity and that some ability to affect other neurotransmitter systems may be a necessary but not sufficient requirement for antiobsessional activity. These data lend only partial support to a serotonin hypothesis of obsessive-compulsive disorder.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Meta-Analysis
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Naphthylamine / analogs & derivatives
-
1-Naphthylamine / therapeutic use
-
Adult
-
Ambulatory Care
-
Clinical Trials as Topic
-
Clomipramine / therapeutic use
-
Double-Blind Method
-
Female
-
Fluoxetine / therapeutic use
-
Fluvoxamine
-
Humans
-
Male
-
Meta-Analysis as Topic
-
Obsessive-Compulsive Disorder / drug therapy*
-
Obsessive-Compulsive Disorder / physiopathology
-
Obsessive-Compulsive Disorder / psychology
-
Oximes / therapeutic use*
-
Placebos
-
Psychiatric Status Rating Scales
-
Serotonin / physiology
-
Serotonin Antagonists / therapeutic use*
-
Sertraline
Substances
-
Oximes
-
Placebos
-
Serotonin Antagonists
-
Fluoxetine
-
Serotonin
-
1-Naphthylamine
-
Clomipramine
-
Fluvoxamine
-
Sertraline